Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors: Exploring the Impact of Ring Size on Structure−Activity Relationships
Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 1996-09, Vol.39 (20), p.4125-4130 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4130 |
---|---|
container_issue | 20 |
container_start_page | 4125 |
container_title | Journal of medicinal chemistry |
container_volume | 39 |
creator | Romines, Karen R Morris, Jeanette K Howe, W. Jeffrey Tomich, Paul K Horng, Miao-Miao Chong, Kong-Teck Hinshaw, Roger R Anderson, David J Strohbach, Joseph W Turner, Steve R Mizsak, Steve A |
description | Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM. |
doi_str_mv | 10.1021/jm960296c |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78382270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78382270</sourcerecordid><originalsourceid>FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</originalsourceid><addsrcrecordid>eNptkc1u1DAURiMEKtPCggdA8gKQWAT8l9jurgyFGakSVaewtTyOzXiaxMF2qoYVS9iy4f36JGSU0bBhdaV7jq6uvi_LniH4BkGM3m4bUUIsSv0gm6ECw5xySB9mMwgxznGJyePsOMYthJAgTI6yI84JYkzMsj_zQdde1TdD3Q1Btb41Eai2Av_2ldsMVfAjnmAEi-UXcBl8MioasGw3bu2SD_H0_scvcH7X1T649itImxE2ndIJeAuudquV-26Ab8EqhV6nPpj7n7_PdHK3Lg3gytQqOd_Gjevik-yRVXU0T_fzJPv84fx6vsgvPn1czs8uckWYSLnhnHKFK46FQmWhIScUI2pLZaiFmnCB18RaxlBRFMwSAa3RXFeC2oqKwpKT7NV0twv-W29iko2L2tS1ao3vo2SccIwZHMXXk6iDjzEYK7vgGhUGiaDclSAPJYzu8_3Rft2Y6mDuUx_5iz1XUavajrlrFw8awQQyQUctnzQXk7k7YBVuZMkIK-T15UoSSN6_Wy2o3L34cvKVjnLr-9COyf3nvb895q6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78382270</pqid></control><display><type>article</type><title>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors: Exploring the Impact of Ring Size on Structure−Activity Relationships</title><source>ACS Publications</source><source>MEDLINE</source><creator>Romines, Karen R ; Morris, Jeanette K ; Howe, W. Jeffrey ; Tomich, Paul K ; Horng, Miao-Miao ; Chong, Kong-Teck ; Hinshaw, Roger R ; Anderson, David J ; Strohbach, Joseph W ; Turner, Steve R ; Mizsak, Steve A</creator><creatorcontrib>Romines, Karen R ; Morris, Jeanette K ; Howe, W. Jeffrey ; Tomich, Paul K ; Horng, Miao-Miao ; Chong, Kong-Teck ; Hinshaw, Roger R ; Anderson, David J ; Strohbach, Joseph W ; Turner, Steve R ; Mizsak, Steve A</creatorcontrib><description>Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm960296c</identifier><identifier>PMID: 8831779</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>AIDS/HIV ; Anti-HIV Agents - chemical synthesis ; Anti-HIV Agents - metabolism ; Anti-HIV Agents - pharmacology ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Aspartic Acid Endopeptidases - antagonists & inhibitors ; Aspartic Acid Endopeptidases - chemistry ; Aspartic Acid Endopeptidases - metabolism ; Binding Sites ; Biological and medical sciences ; Crystallography, X-Ray ; Cyclization ; HIV Protease ; HIV Protease Inhibitors - chemical synthesis ; HIV Protease Inhibitors - metabolism ; HIV Protease Inhibitors - pharmacology ; Medical sciences ; Models, Molecular ; Molecular Structure ; Pharmacology. Drug treatments ; Protein Conformation ; Pyrones - chemistry ; Pyrones - metabolism ; Pyrones - pharmacology ; Structure-Activity Relationship ; Sulfonamides - chemistry</subject><ispartof>Journal of medicinal chemistry, 1996-09, Vol.39 (20), p.4125-4130</ispartof><rights>Copyright © 1996 American Chemical Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</citedby><cites>FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm960296c$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm960296c$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3230794$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8831779$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romines, Karen R</creatorcontrib><creatorcontrib>Morris, Jeanette K</creatorcontrib><creatorcontrib>Howe, W. Jeffrey</creatorcontrib><creatorcontrib>Tomich, Paul K</creatorcontrib><creatorcontrib>Horng, Miao-Miao</creatorcontrib><creatorcontrib>Chong, Kong-Teck</creatorcontrib><creatorcontrib>Hinshaw, Roger R</creatorcontrib><creatorcontrib>Anderson, David J</creatorcontrib><creatorcontrib>Strohbach, Joseph W</creatorcontrib><creatorcontrib>Turner, Steve R</creatorcontrib><creatorcontrib>Mizsak, Steve A</creatorcontrib><title>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors: Exploring the Impact of Ring Size on Structure−Activity Relationships</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.</description><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - chemical synthesis</subject><subject>Anti-HIV Agents - metabolism</subject><subject>Anti-HIV Agents - pharmacology</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Aspartic Acid Endopeptidases - antagonists & inhibitors</subject><subject>Aspartic Acid Endopeptidases - chemistry</subject><subject>Aspartic Acid Endopeptidases - metabolism</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>Crystallography, X-Ray</subject><subject>Cyclization</subject><subject>HIV Protease</subject><subject>HIV Protease Inhibitors - chemical synthesis</subject><subject>HIV Protease Inhibitors - metabolism</subject><subject>HIV Protease Inhibitors - pharmacology</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Molecular Structure</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Conformation</subject><subject>Pyrones - chemistry</subject><subject>Pyrones - metabolism</subject><subject>Pyrones - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>Sulfonamides - chemistry</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc1u1DAURiMEKtPCggdA8gKQWAT8l9jurgyFGakSVaewtTyOzXiaxMF2qoYVS9iy4f36JGSU0bBhdaV7jq6uvi_LniH4BkGM3m4bUUIsSv0gm6ECw5xySB9mMwgxznGJyePsOMYthJAgTI6yI84JYkzMsj_zQdde1TdD3Q1Btb41Eai2Av_2ldsMVfAjnmAEi-UXcBl8MioasGw3bu2SD_H0_scvcH7X1T649itImxE2ndIJeAuudquV-26Ab8EqhV6nPpj7n7_PdHK3Lg3gytQqOd_Gjevik-yRVXU0T_fzJPv84fx6vsgvPn1czs8uckWYSLnhnHKFK46FQmWhIScUI2pLZaiFmnCB18RaxlBRFMwSAa3RXFeC2oqKwpKT7NV0twv-W29iko2L2tS1ao3vo2SccIwZHMXXk6iDjzEYK7vgGhUGiaDclSAPJYzu8_3Rft2Y6mDuUx_5iz1XUavajrlrFw8awQQyQUctnzQXk7k7YBVuZMkIK-T15UoSSN6_Wy2o3L34cvKVjnLr-9COyf3nvb895q6k</recordid><startdate>19960927</startdate><enddate>19960927</enddate><creator>Romines, Karen R</creator><creator>Morris, Jeanette K</creator><creator>Howe, W. Jeffrey</creator><creator>Tomich, Paul K</creator><creator>Horng, Miao-Miao</creator><creator>Chong, Kong-Teck</creator><creator>Hinshaw, Roger R</creator><creator>Anderson, David J</creator><creator>Strohbach, Joseph W</creator><creator>Turner, Steve R</creator><creator>Mizsak, Steve A</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19960927</creationdate><title>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors: Exploring the Impact of Ring Size on Structure−Activity Relationships</title><author>Romines, Karen R ; Morris, Jeanette K ; Howe, W. Jeffrey ; Tomich, Paul K ; Horng, Miao-Miao ; Chong, Kong-Teck ; Hinshaw, Roger R ; Anderson, David J ; Strohbach, Joseph W ; Turner, Steve R ; Mizsak, Steve A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a379t-e8848a2d829a165c0834214f6ae4f0c3892b3ff7715557f390fec8cd94fd495f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - chemical synthesis</topic><topic>Anti-HIV Agents - metabolism</topic><topic>Anti-HIV Agents - pharmacology</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Aspartic Acid Endopeptidases - antagonists & inhibitors</topic><topic>Aspartic Acid Endopeptidases - chemistry</topic><topic>Aspartic Acid Endopeptidases - metabolism</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>Crystallography, X-Ray</topic><topic>Cyclization</topic><topic>HIV Protease</topic><topic>HIV Protease Inhibitors - chemical synthesis</topic><topic>HIV Protease Inhibitors - metabolism</topic><topic>HIV Protease Inhibitors - pharmacology</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Molecular Structure</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Conformation</topic><topic>Pyrones - chemistry</topic><topic>Pyrones - metabolism</topic><topic>Pyrones - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>Sulfonamides - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romines, Karen R</creatorcontrib><creatorcontrib>Morris, Jeanette K</creatorcontrib><creatorcontrib>Howe, W. Jeffrey</creatorcontrib><creatorcontrib>Tomich, Paul K</creatorcontrib><creatorcontrib>Horng, Miao-Miao</creatorcontrib><creatorcontrib>Chong, Kong-Teck</creatorcontrib><creatorcontrib>Hinshaw, Roger R</creatorcontrib><creatorcontrib>Anderson, David J</creatorcontrib><creatorcontrib>Strohbach, Joseph W</creatorcontrib><creatorcontrib>Turner, Steve R</creatorcontrib><creatorcontrib>Mizsak, Steve A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romines, Karen R</au><au>Morris, Jeanette K</au><au>Howe, W. Jeffrey</au><au>Tomich, Paul K</au><au>Horng, Miao-Miao</au><au>Chong, Kong-Teck</au><au>Hinshaw, Roger R</au><au>Anderson, David J</au><au>Strohbach, Joseph W</au><au>Turner, Steve R</au><au>Mizsak, Steve A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors: Exploring the Impact of Ring Size on Structure−Activity Relationships</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1996-09-27</date><risdate>1996</risdate><volume>39</volume><issue>20</issue><spage>4125</spage><epage>4130</epage><pages>4125-4130</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Previously, 3-substituted cycloalkylpyranones, such as 2d, have proven to be effective inhibitors of HIV protease. In an initial series of 3-(1-phenylpropyl) derivatives with various cycloalkyl ring sizes, the cyclooctyl analog was the most potent. We became interested in exploring the influence of other structural changes, such as substitution on the phenyl ring and saturation of the 5,6-double bond, on the cycloalkyl ring size structure−activity relationship (SAR). Saturation of the 5,6-double bond in the pyrone ring significantly impacts the SAR, altering the optimal ring size from eight to six. Substitution of a sulfonamide at the meta position of the phenyl ring dramatically increases the potency of these inhibitors, but it does not change the optimal ring size in either the cycloalkylpyranone or the cycloalkyldihydropyrone series. This work has led to the identification of compounds with superb binding affinity for the HIV protease (K i values in the 10−50 pM range). In addition, the cycloalkyldihydropyrones showed excellent antiviral activity in cell culture, with ED50 values as low as 1 μM.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8831779</pmid><doi>10.1021/jm960296c</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1996-09, Vol.39 (20), p.4125-4130 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_78382270 |
source | ACS Publications; MEDLINE |
subjects | AIDS/HIV Anti-HIV Agents - chemical synthesis Anti-HIV Agents - metabolism Anti-HIV Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Aspartic Acid Endopeptidases - antagonists & inhibitors Aspartic Acid Endopeptidases - chemistry Aspartic Acid Endopeptidases - metabolism Binding Sites Biological and medical sciences Crystallography, X-Ray Cyclization HIV Protease HIV Protease Inhibitors - chemical synthesis HIV Protease Inhibitors - metabolism HIV Protease Inhibitors - pharmacology Medical sciences Models, Molecular Molecular Structure Pharmacology. Drug treatments Protein Conformation Pyrones - chemistry Pyrones - metabolism Pyrones - pharmacology Structure-Activity Relationship Sulfonamides - chemistry |
title | Cycloalkylpyranones and Cycloalkyldihydropyrones as HIV Protease Inhibitors: Exploring the Impact of Ring Size on Structure−Activity Relationships |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A36%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cycloalkylpyranones%20and%20Cycloalkyldihydropyrones%20as%20HIV%20Protease%20Inhibitors:%E2%80%89%20Exploring%20the%20Impact%20of%20Ring%20Size%20on%20Structure%E2%88%92Activity%20Relationships&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Romines,%20Karen%20R&rft.date=1996-09-27&rft.volume=39&rft.issue=20&rft.spage=4125&rft.epage=4130&rft.pages=4125-4130&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm960296c&rft_dat=%3Cproquest_cross%3E78382270%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78382270&rft_id=info:pmid/8831779&rfr_iscdi=true |